Featured Story | By Max Bayer Leaps by Bayer, the investment arm of the Big Pharma, plans to more than double the pace of its investments through 2024 with another €1.3 billion for new ventures through 2024. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Sage Therapeutics was mostly focussed on reviewing safety for its Alzheimer’s disease drug, but early data shows the therapy may also improve executive performance, learning and memory in patients with mild cognitive impairment and dementia—but there's a catch. read more By Gabrielle Masson Three more biotech companies have joined the unfortunate—but increasingly common—layoff trend, fueling the epic and growing wave of industry layoffs. With more than 30 layoffs tallied by Fierce Biotech, the overpopulated industry is being forced to cut down. read more Sponsored by: Pfizer Reshaping the understanding of enteric nervous system (ENS) dysfunction and the progression of Parkinson’s, Pfizer CentreOne helped Enterin synthesize a better chemistry for its lead candidate. read more By Nick Paul Taylor Pharming thinks it has the data to support approval of its ex-Novartis rare disease drug. With a phase 2/3 trial of the PI3Kδ inhibitor hitting its co-primary endpoints, Pharming is preparing to file for approvals in the second quarter. read more By Nick Paul Taylor Finch Therapeutics has joined the ranks of biotechs that are narrowing their focus. With its lead program under clinical hold, the microbiome specialist has pulled out of a planned study in chronic hepatitis B. read more By Annalee Armstrong SAB Biotherapeutics is hoping to continue work on its COVID-19 antibody treatment after the National Institutes of Health shut down a funded phase 3 clinical trial when the omicron wave slowed earlier this year. read more By Gabrielle Masson Myeloid Therapeutics and Prime Medicine have signed an exclusive option and research collaboration to develop Myeloid’s RNA-based gene-editing technology, dubbed “RetroT." Prime is shelling out $45 million upfront for the opportunity. read more By Andrea Park No, it’s not an April Fool’s joke—BD officially bid farewell to its longstanding diabetes business on Friday, as the newly formed Embecta made its public debut on the Nasdaq. read more By Eric Sagonowsky When Sanofi unveiled plans to spin off its European active pharmaceutical ingredients unit back in early 2020, the world looked quite different. But more than two years and a global pandemic later, Sanofi is nearing the end of the spinoff process. read more By Robert King The House passed legislation Thursday to cap insulin costs at $35 a month for both Medicare and private plans, but it remains unclear whether the legislation would change in the Senate where a bipartisan effort is happening. read more By Gareth Macdonald Spanish cancer services firm Medsir has set its sights on Latin America by forging a partnership with Brazilian oncology research chain Oncoclínicas. read more By Kevin Dunleavy The FDA has extended its target date for approval of Merck's next-generation pneumococcal vaccine Vaxneuvance in kids by three months. Before it signs off the shot for kids ages 6 weeks through 17, the U.S. regulator wants to see additional analyses of data. The approval is key as Merck hopes to gain an edge over Pfizer in this important age group. read more By Angus Liu FDA's oncology chief Richard Pazdur defends the agency's rejection of Eli Lilly and Innovent Biologics' PD-1 inhibitor. U.S. lawmakers are working to reduce America's supply chain reliance on China. Insilico Medicine shows its artificial intelligence drug discovery engine works in age-related diseases. And more. read more By Max Bayer John Mascola is leaving the Vaccine Research Center—NIAID's R&D hub—after 22 years including nine as director. Former Merck CEO Ken Frazier is hopping onto Eikon's board, the third former exec from the Big Pharma to join the startup this year. Bone Therapeutics is losing four members of its C-suite after cutting 25% of its workforce in early March. read more Resources Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: H1 Read why many MSLs are still challenged in developing integrated strategies to increase the volume of meaningful engagements. Download this industry report to find out what the top challenges are and suggestion strategies to solve them. Download now. Sponsored by: Medidata, a Dassault Systèmes company The landscape of clinical trials has been permanently changed. Today's trials require sponsors to modernize their use of technology and data to adapt. This eBook provides an overview of how sponsors can empower trials with real-time performance data to improve study integrity, reduce risks, optimize patient safety, and increase trial success rates. Sponsored by: Thermo Fisher Scientific Learn how to navigate the top manufacturing challenges and achieve a seamless transition from discovery to clinical manufacturing across the CAR T-cell therapy workflow. Sponsored by: Oracle Health Sciences Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research. Sponsored by: Oracle Health Sciences How to overcome top challenges faced in decentralized trials. Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Accelerating Immuno-Oncology and Oncology Drug Development Using Humanized Mice Live & Recorded on: Thursday, April 21, 2022 | 12pm ET / 9am PT Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 
